BNP PARIBAS ASSET MANAGEMENT Holding S.A. Buys 10,888 Shares of Humana Inc. $HUM

Key Points

• BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Humana Inc. by 61.5% during the first quarter, now owning 28,591 shares valued at approximately $7.57 million.
• Other institutional investors have also ramped up their stakes in Humana, with Vanguard Group increasing its holdings by 8.9%, totaling almost $3.7 billion in value.
• Humana's recent earnings report showed a slight miss on EPS expectations, reporting $6.27 compared to the consensus estimate of $6.32, but did see a 9.6% increase in quarterly revenue year-over-year.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 61.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,591 shares of the insurance provider's stock after buying an additional 10,888 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s holdings in Humana were worth $7,565,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Deutsche Bank AG raised its holdings in Humana by 18.2% in the fourth quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock worth $160,185,000 after purchasing an additional 97,071 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Humana during the 1st quarter worth approximately $1,309,000. Fred Alger Management LLC acquired a new position in shares of Humana in the fourth quarter valued at approximately $451,000. Clearline Capital LP bought a new stake in Humana in the 4th quarter valued at $1,102,000. Finally, Envestnet Asset Management Inc. increased its holdings in Humana by 2.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock worth $33,256,000 after purchasing an additional 2,950 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

Shares of HUM traded up $4.2280 during midday trading on Thursday, reaching $294.2280. The stock had a trading volume of 1,471,312 shares, compared to its average volume of 1,866,874. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a 50 day simple moving average of $247.28 and a 200-day simple moving average of $253.70. The firm has a market cap of $35.39 billion, a PE ratio of 22.58, a P/E/G ratio of 1.71 and a beta of 0.44. Humana Inc. has a one year low of $206.87 and a one year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter in the prior year, the company earned $6.96 EPS. Humana's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana's dividend payout ratio is currently 27.17%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on HUM shares. Royal Bank Of Canada boosted their price target on Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a report on Thursday. Oppenheimer boosted their target price on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Bank of America decreased their price target on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Finally, Barclays set a $275.00 target price on shares of Humana and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Seven analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to data from MarketBeat, Humana currently has a consensus rating of "Hold" and a consensus price target of $283.29.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.